Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
Share
Why It Matters
Syndax stopped testing a medicine for lung disease because it didn't work well enough. When a drug fails in testing, it means less chance for the company to earn money soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.